PT-141 Bremelanotide
FDA ApprovedStrong EvidenceBremelanotide (PT-141)
Same compound as PT-141 — some vendors list bremelanotide's generic name. FDA-approved for HSDD in premenopausal women.
Half-Life
~2.7 hours
Molecular Weight
1025.2 g/mol
PT-141 Bremelanotide is the same compound as PT-141 — some vendors list both names. Bremelanotide is the generic (INN) name; PT-141 is the research designation. FDA-approved as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. Acts centrally through MC3R/MC4R to enhance sexual motivation. See PT-141 profile for full details.
Also Known As
PT-141BremelanotideVyleesi
Amino Acid Sequence
Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH
Reconstitution
Available as Vyleesi autoinjector. Research peptide: reconstitute with bacteriostatic water.
Open Reconstitution Calculator →